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Abstract 
Maspin is a non-inhibitory member of the serpin family that affects cell behaviours related to migration 
and survival. We have previously shown that peptides of the isolated G α-helix (G-helix) domain of 
maspin show bioactivity. Migration, invasion, adhesion and proliferation of vascular smooth muscle cells 
(VSMC) are important processes that contribute to the build-up of atherosclerotic plaques. Here we report 
the use of functional assays of these behaviours to investigate whether other maspin-derived peptides 
impact directly on VSMC; focusing on potential anti-atherogenic properties. We designed 18 new 
peptides from the structural moieties of maspin above ten amino acid residues in length and considered 
them beside the existing G-helix peptides. Of the novel peptides screened those with the sequences of 
maspin strand 4 and 5 of beta sheet B (S4B and S5B) reduced VSMC migration, invasion and 
proliferation, as well as increasing cell adhesion. A longer peptide combining these consecutive 
sequences showed a potentiation of responses, and a 7-mer contained all essential elements for 
functionality. This is the first time that these parts of maspin have been highlighted as having key roles 
affecting cell function. We present evidence for a mechanism whereby S4B and S5B act through ERK1/2 
and AMP-activated protein kinase (AMPK) to influence VSMC responses. 
 
Graphic Abstract 
 
Schematic depiction of the effect of maspin peptides on VSMC behaviours 
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Abbreviations 
VSMC, vascular smooth muscle cells; S4B, strand 4 of beta sheet B; S5B strand 5 of beta sheet B; RCL, 
reactive centre loop; AMPK, AMP-activated protein kinase; G-helix, G -helix; S1A, strand 1 of beta 
sheet A;  S2C, strand 2 of  beta sheet C. 
 
Introduction 
The non-inhibitory serpin maspin (SerpinB5) affects cell behaviours that are consistent with its initial 
identification as a tumour metastasis suppressor in breast carcinoma [1]. Since then numerous studies 
have demonstrated that it decreases tumour growth, invasion, metastasis and angiogenesis (recently 
reviewed [2]). Maspin affects a range of cell types including those that do not express it. Commonly 
expressed by epithelial cells and lost in carcinogenesis, it has also been shown to be expressed by and 
influence endothelial cells [3], lymphocytes [4] and smooth muscle cells [5]. We have shown that maspin 
affects the functions of vascular smooth muscle cells (VSMC) that impact on the development of 
atherosclerosis; also referred to as atherogenesis [6-8]. 
VSMC migration and proliferation are important in the response to injury and the pathogenesis of 
vascular disease [9, 10]. VSMC surrounding normal blood vessels are differentiated which means that 
they do not proliferate or migrate [11]. One of the responses to vascular injury is that VSMC 
dedifferentiate, becoming motile and proliferative [11]. Whether migration and proliferation of VSMC are 
beneficial or not depends on the stage of the disease. Migration of VSMC to sites of vascular injury is 
involved in the early stages of atherosclerosis and in restenosis following angioplasty; the VSMC then 
proliferate in situ. The balance between proliferation and apoptosis of VSMC is important in 
atherosclerotic plaque development. Once an atherosclerotic plaque is established it is dependent on 
VSMC for stability – plaque rupture triggers thrombus formation, leading to heart attack or stroke. The 
VSMC functions contributing to these behaviours can be influenced by maspin which prevents migration, 
invasion and proliferation, while increasing adhesion – consequences that can generally be thought of as 
anti-atherogenic. 
We have previously demonstrated that bioactive peptides from the maspin structure can influence VSMC 
behaviour. We found that a peptide of the G -helix in isolation (G-helix) replicated the effect of full-
length maspin in reducing the migration of a variety of cell types including VSMC, and contributed to the 
action of maspin on cell adhesion [8]. Subsequently other maspin derived peptides have been shown to 
have biological effects. Peptides from beta sheets strand 1A (S1A) and strand 2C (S2C) of maspin were 
reported to cause epithelial cell adhesion [12]. In support of our demonstration of the influence of the G-
helix on cell migration and adhesion, this region of maspin has independently been shown to affect these 
functions in endothelial cells, resulting in the inhibition of angiogenesis when incorporated into 
supramolecular nanostructures [13]. 
How maspin derived peptides affect cell function is an intriguing question. It is possible that they 
replicate a subset of the protein-protein interactions of the whole protein. Like PAI-2 [14], maspin does 
not have a defined signal sequence but is found in both intra- and extra-cellular locations [8, 12, 15], with 
binding partners characterized in both contexts. We have been interested in how maspin in the 
extracellular environment can influence VSMC behaviour, since discovering that it acts without being 
able to directly inhibit serine protease activity [6]. We found that maspin directly bound β1 integrins on 
the VSMC surface affecting adhesion and migration [7]. Maspin – integrin interactions have also been 
demonstrated on the surface of epithelial and endothelial cells [3, 16]. Overall these studies imply that 
there are both direct and indirect contributions of maspin to major cellular processes. 
The cell-signalling pathways associated with maspin are not well understood, and have not been reported 
for maspin peptides previously. There is some evidence for an overlap with integrin-associated signalling 
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pathways. The interaction of maspin with small GTPases Rac-1 and Cdc42 has been reported to modulate 
PI3K and ERK1/2 [17] and JNK kinase and AP-1 [18] in breast carcinoma and FAK in endothelial cells 
[3]. FAK along with Akt has been implicated in how maspin influences apoptosis and angiogenesis in 
prostate cancer [19]. Multiple signals have been associated with VSMC proliferation and migration, with 
AMPK (AMP-activated protein kinase), ERK 1/2 and Akt commonly reported [20], however there have 
been no previous reports of maspin interacting with these signalling pathways in VSMC. 
In this study we designed eighteen new peptides from the structural moieties of maspin, in addition to the 
G-helix, and functionally screened them to determine how they influenced the adhesion and proliferation 
of VSMC. The initial screens indicated that six peptides could alter cellular activity. We designed specific 
peptide controls for each of these six peptides and subsequently identified two peptides which displayed 
significant bioactivities. Strand 4 & 5 of maspin beta sheet B (S4B and S5B) decreased VSMC 
proliferation, migration, and invasion, while increasing adhesion. As the sequences for these regions are 
consecutive we tested a long peptide of the sequences of S4B and S5B together – which showed enhanced 
effects in comparison to the isolated peptides.  Sequential removal of residues from either end of S5B 
allowed the identification of a minimal active region comprising a 7-mer. Insights into how these 
sequences influence VSMC function were provided by studies demonstrating changes in ERK1/2 and 
AMPK signalling in response to S4B and S5B. 
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Materials and Methods 
Peptides, antibodies and materials - 19 peptides corresponding to discrete structural moieties of maspin 
were synthesized by Pepceuticals (Leicestershire, UK), with biotin-aHx on their N terminus and an amide 
on their C terminus. Peptides were prepared at 95% purity and dissolved in dimethyl sulfoxide (DMSO) 
to a concentration of 10mM. Test peptides are detailed in table 1. The G-helix control peptide was used as 
a comparison for the initial screens [8]; additional control peptides were subsequently designed to match 
the charge and composition of their respective test peptides (Table 2). A long maspin peptide and 
matching control were synthesized; this comprised the total length of peptides S4B and S5B, which are 
adjacent in the maspin amino acid sequence (Table 1). Attenuated S5B peptides are detailed in Table 3 
Peptides were usually used at a final concentration of 10µM in assays, which had previously been defined 
as optimal [8]. Anti- β1 (Mab17781, 1:1000) integrin was from R&D Systems (Abingdon, UK). β3 
integrin (MAB20232, 1:1000) MAb was purchased from Millipore (Hertfordshire, UK). Antibodies to 
ERK1/2 (9102S, 1:1000) and ERK1/2P (9101, 1:1000) were from New England Biolabs UK 
(Hertfordshire, UK). Anti- AMPKa (GTX50863, 1:1000) and AMPKaP (GTX63165, 1:1000) were from 
Source Bioscience (Nottingham, UK). Fluorescent dye DilC16 was from Life Technologies (Paisley, 
UK). WST-1 was purchased from Roche (Burgess Hill, UK). All other reagents were purchased from 
Sigma Aldrich. 
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Table 1 
Peptide Sequence 
RCL 329-DGGDSIEVPGARIL 
Helix A 4-LQLANSAFAVDLFKQLCEKE 
Helix B 33-ICLSTSLSLAQVGA 
Helix C 48-DTANEIGQVLH 
Helix D 65-DIPFGFQTVTSDVNKL 
Helix G 236-EDESTGLEKIEKQLN 
Helix F 126-EETKGQINNSIKDLTD 
Helix H 252-NSESLSQWTN 
Helix I 285-KACLENLGLK 
S2A 74-YSLKLIKRLYVDKS 
S3A 158-KILVVNAAYFVG 
S5A 317-NVIHKVCLEIT 
S1B 190-TDTKPVQMMNMEA 
S2B 213-NCKIIELPFQN 
S3B 225-HLSMFILLPKD 
S4B 354-FIYIIRHNKT 
S5B 364-RNIIFFGKFC 
S4B/S5B Long 354-FIYIIRHNKTRNIIFFGKFC 
S2C 260-NPSTMANAKVKLSIP 
S3C 181-TKECPFRLNK 
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Table 2 
 
Peptide Sequence 
G Helix Control (C-Pep) EDESTGELKILKQEN 
RCL Control EAAESIDVPAGRIL 
S2A Control YSIRILRKIYVDRS 
S3A Control KIVLLNGGYFLA 
S5A Control TLIHKLCVEIN 
S4/5B Control  FIKNRHTYCG 
S4B/S5B Long Control FIKNRHTYCGFIKNRHTYCG 
 
 
Table 3 
Peptide Sequence 
Minus 1L NIIFFGKFC 
Minus 1R RNIIFFGKF 
Minus 2L IIFFGKFC 
Minus 2R RNIIFFGK 
Minus 3L IFFGKFC 
Minus 3R RNIIFFG 
Minus 4L FFGKFC 
Minus 4R RNIIFF 
Minus 5L FGKFC 
Minus 5R RNIIF 
Minus 6L GKFC 
Minus 6R RNII 
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Cell Culture - Primary aortic smooth muscle cells (referred to as VSMC), were cultured as described 
previously [7] in 231 medium supplemented with smooth muscle cell growth supplement containing 5% 
(v/v) FBS. For some experiments, VSMC were transferred into phenol red free serum-free MEM. VSMC 
were used between passages 3 and 8. HT29 cell line was purchased from ATCC and cultured in DMEM, 
supplemented with 10% (v/v) FBS, L-glutamine and penicillin/streptomycin. All cell culture reagents 
including extracellular matrix (ECM) components were from ThermoFisher Scientific (Paisley, UK). 
Kinetic Adhesion and Proliferation Assay - To screen the 19 maspin peptides for their ability to alter 
adhesion and proliferation of VSMC, an xCELLigence DP real time cell analyser was used according to 
the manufacturer’s instructions (Acea Biosciences Inc., CA, USA). Briefly VSMC were seeded onto an 
xCELLigence E plate at 6000 cells/well with maspin peptides or control. E plates consist of a gold 
microelectrode and attachment/spreading of cells is determined by measuring relative electrical 
impedance across the cell monolayer. Adhesion was determined by recording impedance every 5 minutes 
for 4 hours. Following this 4 hour period, impedance measurements were then taken every 15 minutes for 
up to 72 hours to determine cell proliferation as described previously [21]. In some experiments, E plates 
were coated with ECM components at 5µg/ml for 15 hours at 4°C and then blocked with 1% (w/v) BSA 
for 30 minutes at 37°C prior to the addition of VSMC.  
Endpoint Adhesion Assay - Endpoint assays were used to measure cell adhesion to individual ECM 
components or fibrillar matrix. Wells were coated with fibrillar matrix made by HT29 cells as described 
previously [8] or individual ECM components as for the kinetic assays. VSMC were labelled with DilC16 
fluorescent dye in phenol red free, serum free MEM for 30 minutes at 37°C, then centrifuged at 800g for 
5 minutes and resuspended in fresh medium. Cells were incubated with maspin peptide for 30 minutes at 
37°C, prior to plating onto the fibrillar matrix/ECM coated wells at a density of 6000/well. Cells were 
incubated at 37 °C for 45 minutes then washed with PBS to remove non-adherent cells. Fresh medium 
was added to each well and fluorescence intensity of the plate was measured at Ex544, Em590 using a 
FLUOstar Omega plate reader (BMG Labtech, Aylesbury, UK). In some experiments labelled VSMC 
were pre-treated with anti-β1 or anti-β3 integrin at 5µg/ml for 30 minutes at 37°C. 
Endpoint Proliferation Assay - VSMC were plated onto 96 wells at a density of 5000 cells/well and 
cultured overnight. The cells were serum-starved in 0.5% (v/v) FBS containing medium for 24 hours, 
then cultured in complete growth medium containing maspin peptides for a further 24 hours. To quantify 
cell proliferation, WST-1 was added to each well and cells were incubated at 37°C for 5 hours to allow 
colour change to develop. Absorbance at 490nm was measured using a FLUOstar Omega plate reader. 
Kinetic Migration and Invasion Assay - Migration and invasion of VSMC in response to maspin peptides 
was determined using an xCELLigence DP according to the manufacturer’s instructions. Migration was 
as described previously [21]. Invasion of VSMC was investigated using CIM plates coated with collagen 
gel. 90% (w/v) rat tail collagen, 10x DMEM, 10mM NaOH was added to the top chamber of the CIM 
plate and allowed to polymerize at 37°C. VSMC were prepared as for migration assays and added to the 
top of the collagen gel. Impedance measurements were recorded every 15 minutes over a 24 hour period. 
Cell index plots were used to calculate area under curve values to give one overall measurement of cell 
migration/invasion for each well of the xCELLigence plate using Origin Software (Silverdale Scientific, 
Buckinghamshire, UK). These values were then expressed as percentage migration relative to control 
peptide. 
Cell-based ELISA - Activation of signalling molecules ERK1/2 and AMPK in VSMC in response to 
maspin peptide treatment was determined by semi-quantitative cell-based ELISA. VSMC were seeded 
onto 96 wells at a density of 5000/well and cultured overnight. The cells were serum-starved for 24 hours, 
then cultured in complete growth medium containing maspin peptides for a further 24 hours. Medium was 
removed from the wells and cells were fixed for 20 minutes at room temperature in 4% (w/v) 
paraformaldehyde. Fixed cells were then washed x3 for 5 minutes with PBS +0.1% (v/v) Tween 20, 
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followed by incubation with 2% (v/v) hydrogen peroxide solution in PBS for 20 minutes at room 
temperature. Wells were blocked with 5% (w/v) BSA for 1 hour followed by incubation with primary 
antibody overnight at 4°C. Cells were then incubated with an HRP-conjugated secondary antibody for 1 
hour at room temperature and developed with TMB substrate. The reaction was stopped with 2.5M H2SO4 
and absorbency of the plate was measured at 450nm using FLUOstar Omega plate reader. 
Statistical Analysis - Statistical analysis was carried out using Microsoft Excel and Origin software 
packages. Statistical analysis was performed on raw data, prior to processing to data relative to control 
which was used for presentation to aid understanding. Data are presented as mean±SEM. For single 
comparison tests, significance was judged using Student’s t test. For multiple comparisons ANOVA 
followed by Tukey’s post-test was used. A value of p<0.05 was considered statistically significant. 
 
Results 
S4B and S5B are potentially important structural motifs for maspin function 
A panel of 19 peptides was designed, corresponding to discrete structural motifs in the maspin molecule 
(Table 1). The peptides were initially screened using for their ability to affect VSMC adhesion (Figure 1) 
and proliferation (Figure 2). We had previously demonstrated that 10µM was the optimal concentration 
for the use of G-helix peptides in cell culture models [8], so used this as a starting point. The effectiveness 
of this concentration was verified with some peptides (supplementary figure 1). 
The changes in VSMC cell adhesion (Figure 1A) and proliferation (Figure 2A) in the presence of peptides 
on six matrix conditions were determined. Peptides RCL (reactive centre loop), S2A, S5A, S4B and S5B 
significantly increased VSMC adhesion to ECM components when compared to the control peptide C-
Pep used in previous studies [8] (Table 2). When specific control peptides were designed to be matched 
for charge and length to each of these peptides, S4B and S5B increased cell adhesion by at least 50% 
using an endpoint adhesion assay, when compared to a peptide-specific control (Figure 1B and Table 2). 
RCL, S2A and S5A showed no significant increase compared to their specific controls (supplementary 
Figure 2). S4B was also able to increase VSMC adhesion to fibrillar matrix produced by the HT29 cell 
line by 48 ± 10%, whereas S5B showed no significant increase (Figure 1B). We have previously 
demonstrated that the ability of maspin to increase adhesion to fibrillar matrix was not dependent on the 
type of cell used to deposit the matrix [8]. 
Peptides G helix, S3A, S4B and S5B were identified from the initial screen against C-Pep as able to 
significantly reduce VSM  proliferation (Figure 2A). When these were further tested only S4B and S5B 
significantly reduced proliferation by at least 17% compared to the peptide-specific control (Figure 2B). 
Titration of the S4B and S5B peptides in proliferation assays demonstrate that 10µM is the optimal for 
these peptides (supplementary figure 1). The effect of S4B and S5B on other cell types was investigated 
and it would appear that there is specificity to VSMC (supplementary figure 2). G helix and S3A caused 
no significant reduction in proliferation compared to their specific controls when assessed by WST-1 
viability assay (supplementary figure 3). This was disappointing as S3A had the most universal ability to 
decrease proliferation in the initial screen against the C-Pep peptide.  Overall the initial high through put 
screen, followed by validation experiments using endpoint assays and peptide-specific controls 
demonstrated that the peptides in isolation could influence important VSMC functions. It also allowed the 
identification of structural motifs of maspin that have not previously been linked to functional 
importance. S4B and S5B are potentially critical for the actions of maspin as both can increase the 
adhesion and decrease the proliferation of VSMC. 
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Peptides S4B and S5B decrease migration and invasion of VSMC 
The importance of the motifs S4B and S5B for the actions of maspin was further investigated by 
determining the effect of their corresponding peptides on the migration (Figure 3A) and invasion (Figure 
3B) of VSMC. S4B and S5B peptides significantly decreased the migration of VSMC by as much as 64% 
when compared to specific control peptide (Figure 3A). Both peptides also reduced the invasion of 
VSMC through a cross-linked collagen gel by 50% compared to control peptide (Figure 3B). These data 
suggest that peptides S4B and S5B in isolation can alter the behaviours of VSMC also shown to be 
mediated by the intact maspin molecule [6]. 
Maspin S4B/S5B long peptide also influences VSMC behaviour 
In the maspin molecule the sequences of S4B and S5B are consecutive. As each peptide individually 
could influence VSMC function, a long maspin peptide consisting of the entire sequence of both of these 
motifs was synthesized (Table 1) in addition to a long peptide control (Table 2). The long maspin peptide 
was then tested for its ability to alter behaviour of VSMC. The long peptide increased VSMC adhesion to 
ECM components and fibrillar matrix compared to long peptide control by between 35-125% (Figure 
4A). In particular adhesion to vitronectin was dramatically increased, demonstrating an increase in 
adhesion of 125±31%. The long peptide also significantly decreased proliferation by 27±18% (Figure 4B) 
and migration by 60±4% of VSMC (Figure 4C) compared to long peptide control.  So the long peptide 
potentiated the effects observed for S4B and S5B individually. 
Maspin peptides affect cell signalling pathways involved in cell migration 
Having demonstrated that the peptides S4B and S5B alone or when synthesized in combination could 
influence the behaviour of VSMC, we sought to understand the mechanism of action. We investigated the 
effect of maspin peptides on the activation state of signalling molecules AMPK and ERK1/2, which are 
known to be involved in cell migration [22, 23]. Using cell-based ELISA we looked at the effect of 
maspin peptides S4B and S5B on ERK1/2 phosphorylation (Figure 5A) and the effect of the long peptide 
(Figure 5B). All three peptides significantly decreased ERK1/2 phosphorylation by up to 32% in 
comparison to corresponding peptide controls; the total ERK1/2 detected was unchanged. 
In contrast, AMPK phosphorylation was increased by up to 30% in response to S4B and S5B (Figure 5C) 
and long peptide (Figure 5D). AMPK has been previously shown to decrease migration of VSMC [23, 
24]. To test whether the decrease in migration mediated by maspin peptides required AMPK, VSMC were 
treated with the AMPK inhibitor dorsomorphrin and migration in response to the long peptide was 
determined. After treatment with dorsomorphrin, the inhibitory effect of the long peptide on VSMC 
migration was significantly attenuated compared to migration of VSMC treated with the long peptide 
alone (Figure 5E). Dorsomorphrin had no significant effect on VSMC migration in response to the long 
peptide control, suggesting that the long peptide and therefore maspin may act through AMPK to reduce 
cell migration. 
Adhesion by peptide S4B may involve β1 integrin 
We have shown previously that maspin reduces migration of VSMC through interactions with β1 integrin 
[7]. To test whether the increase in cell adhesion observed with maspin peptides also involved β1 integrin, 
VSMC were pre-incubated with blocking antibodies to either β1 or β3 integrin and adhesion to 
fibronectin in response to maspin peptides determined. Treatment with either antibody resulted in a 
significant reduction in S4B mediated cell adhesion compared to cells treated with S4B alone (Figure 5F). 
The anti- β1 reduced the adhesion of VSMC + S4B by 69%, in comparison to the anti- β3 which reduced 
adhesion by 20%. Only cells treated with β1 MAb adhered less than cells treated with S4/5B specific 
control peptide (reduction of 54±12%). Neither antibody had any significant effect on S5B peptide-
mediated adhesion (Jenkinson & Bass, unpublished observations).  
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Identification of minimal active region 
In addition to considering longer peptides we investigated the effect of reducing the size of S5B to 
identify a minimal active region. Peptides were made by sequentially removing amino acid residues from 
each end of S5B. The ability of the shortened peptides to alter adhesion (Figure 6A) and migration 
(Figure 6B) was investigated. The ability of S5B to increase adhesion was maintained until four amino 
acid residues had been removed from the peptide. This indicated that a 7-mer peptide (sequence 
IFFGKFC) contained the essential elements for increasing adhesion. This region was also able to reduce 
migration, when removal of another residue abolished the effect. 
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Discussion 
Here we demonstrate the identification of previously unreported peptides from the sequence of maspin 
that can influence VSMC proliferation, adhesion and migration. It is an evolution of our previous study 
showing that the G-helix of maspin plays an essential role in the effects of the serpin on the migration of a 
variety of cell types including VSMC [8]. This has been confirmed subsequently by others who reported 
effects of the G-helix of maspin on the migration and adhesion of endothelial cells and possible 
application as anti-angiogenic therapy [13]. The potential for the use of peptides from discrete structural 
motifs of serpins as therapeutic agents is of broader interest than those from maspin.  A recent study 
demonstrated the utility of RCL peptides from serpin family members Serp-1 and NSP in the reduction of 
atherosclerotic plaque formation [25]. 
In this study the sequences of all 25 structural domains of maspin were considered and those consisting of 
at least ten amino acid residues synthesized (Table 1). Exceptions to this were peptides of S1B and S2C, 
which were slightly extended to encompass sequence areas previously reported to be involved in cell 
adhesion [12]. Initial high-throughput screens were performed relative to the G-helix control peptide, and 
then specific controls designed for those determined to be of interest.  Representative time points are 
shown in this paper, but the effect of peptides was often maintained throughout the time scale of assays 
(Supplementary figure 4). 
Unexpectedly we found that most of the peptides had at least some significant effect on cell proliferation 
and adhesion. Adhesion was increased by most peptides, with a peptide dependent variation in ECM 
specificity. Only the α-helix I had no effect on VSMC adhesion. Longer term, when assessing 
proliferation fewer of the peptides affected VSMC function; here we concentrated on those decreasing 
proliferation. It is worth noting that ten of the peptides could increase proliferation, again in a fashion 
dependent on which ECM component the cells were grown on; providing possible targets for exploration 
as maspin antagonists in future. 
In line with previous findings [12] S1B and S2C had some effect on cell adhesion, but not as consistently 
or significantly as those observed with peptides from regions RCL, S2A, S5A, S4B and S5B. Endpoint 
adhesion assays were used to verify the results and investigate whether the peptides showed a significant 
difference to control peptides individually matched for charge and size. This was important to rule out 
non-specific effects. S5A and S4B significantly increased adhesion in comparison to their matched 
control; RCL, S2A and S5A did not. Similarly G helix, S3A, S4B and S5B were investigated in endpoint 
proliferation assays against specific controls; again only S5B and S4B caused comparative significant 
decreases. This is the first time that the contributions of these regions to the functionality of maspin (or 
any serpin) have been directly demonstrated. 
There was a mechanistic difference in how S4B and S5B influenced the adhesion of VSMC as although 
both increased it by over 50% on isolated ECM components, there was no enhancement of VSMC 
adhesion to fibrillar matrix in the presence of S5B. The reason for this remains undetermined, but is likely 
related to differences in integrin engagement, as only S4B enhanced adhesion could be reduced by 
integrin function blocking antibodies. Conversely both peptides decreased VSMC proliferation by at least 
20% indicating a similar affect. 
We went on to look at whether S4B and S5B peptides were sufficient for the control of other cell 
functions archetypally ascribed to full length maspin. Both peptides inhibited VSMC migration and 
invasion in comparison to their matched control; migration by >40% and invasion by approximately 50%. 
These are similar to the effects of full length maspin previously reported [6, 26], so allows the probability 
that the peptides are working through a similar mechanism as the full length maspin. The similarity of the 
magnitude of responses to both peptides again allows us to speculate that both are working through the 
same mechanism. 
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It would appear that the effect of S4B and S5B are specific to VSMC as they did not inhibit the growth of 
breast or prostate cancer cell lines.  The effect of the peptides on other functions of these cells has not yet 
been determined. 
A long peptide encompassing the sequences of S4B and S5B together showed a slight enhancement of the 
functional effects demonstrated for the individual S4B and S5B peptides. Notable amongst this was an 
increase in cellular adhesion to vitronectin by 125%.  Stepwise removal of residues from either end of 
S5B allowed the demonstration of a minimal region with the sequence IFFGKFC, which could influence 
adhesion and migration – removal of further residues abolished the effects. 
We demonstrate here that peptides of the S4B and S5B motifs of maspin affect VSMC function in ways 
that could have a positive impact on the initial development of atherosclerotic plaques, or on restenosis 
after angioplasty; these peptides can be thought of as anti-atherogenic. The ability of S4B and S5B to 
decrease VSMC proliferation, migration and invasion, while increasing adhesion imply that they would 
be able to reverse VSMC behaviours required for the formation of atherosclerotic plaques. 
The sequences of S4B and S5B are located near the C-terminus of maspin. They are next to each other in 
both the sequence and the three dimensional structure, where they are found in the hydrophobic core [27]. 
Although not predicted to be on the surface of the molecule these regions are in a position adjacent to a 
solvent accessible cleft, which could provide an insight into the functionality of this region. The 
sequences of S4B and S5B are highly conserved and unique to maspin orthologues (SIB BLAST service), 
implying that this region has an important role in full length maspin. 
To provide insights into the mechanism of action cell signalling pathways were studied. We found 
evidence that S4B and S5B peptides individually and together in the long peptide work through ERK1/2 
and AMPK. All three peptides decreased ERK1/2 activation and increased the levels of active AMPK; in 
addition an AMPK inhibitor partially attenuated the effects of the long peptide on VSMC migration. 
There are numerous studies linking the activation of AMPK to decreases in VSMC proliferation in both 
cell and animal models [20, 24, 28, 29]. This allows a potential explanation for how the downstream 
effects of the peptides are mediated. Suppression of ERK1/2 activation has been linked to a decrease in 
VSMC migration, potentially via an increase in on AMPK activation [20]. The activation of AMPK has 
been reported to decrease the migration of colon cancer cells by a β1 integrin dependent mechanism [30], 
providing a link to the influence of S4B and S5B on adhesion. It has been suggested that AMPK 
activation is anti-atherogenic [24] – providing us with an explanation for these effects of S4B and S5B. 
The relationship between ERK1/2, AMPK and VSMC migration allows us to propose that maspin 
controls cell migration by increasing AMPK activation and decreasing ERK1/2 activation. 
Although the direct influence of maspin on the plasminogen activation system has long been discounted 
[6], reports of a link between the two persist [12, 31, 32].  The ability of the peptides to interfere with 
plasminogen activation, due to exogenous urokinase plasminogen activator (uPA) binding to its cell 
surface receptor (uPAR) was investigated using well established methods [6].  As S4B and S5B were not 
able to alter plasminogen activation, this was not an explanation for how the peptides influence cellular 
function (Bass, unpublished observations). Peptides from other regions of maspin did effect plasminogen 
activation by up to 40% – S2A and S5A significantly enhanced it, while peptides of helices C, D and F 
significantly decreased it (Bass, unpublished observations). 
How the S4B/S5B peptides interacted with the VSMC to induce these effects was not directly addressed. 
The short time required for their influence to be seen indicates a dynamic regulation of cellular processes, 
similar to prior observations with full length maspin [6]. The peptides could either have been taken up 
into cells as recently demonstrated for full length maspin [33] or acting through cell surface receptors as 
discussed. Either of these mechanisms could account for the effects on downstream signalling processes 
demonstrated. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
14 
 
The role of integrins in the action of S4B and S5B was investigated, as we and others have previously 
demonstrated the role of β1 integrins in maspin function [3, 6, 12, 16]. Although the enhancement of cell 
adhesion by S4B was reduced by a β1 blocking antibody, neither peptide interacted directly with Fc-α5β1 
protein as demonstrated for full length maspin (as described [7]. Jenkinson & Bass, unpublished 
observations). The anti- β1 did not affect S5B enhanced adhesion (Jenkinson & Bass, unpublished 
observations) – furthering support for the two peptides influencing cell adhesion in different ways. 
Peptides are widely under investigation for their beneficial effects which can be exploited therapeutically; 
this includes those derived from serpin structures. Peptides targeting the angiogenic growth factor systems 
and integrins have been found to be useful as angiogenesis targeting anti-cancer and heart disease 
therapies (Reviewed [34]). Indeed, nanostructures incorporating the G-helix of maspin have been shown 
to confer anti-angiogenic affects [13]. Peptides from pigment epithelial derived factor (PEDF; 
SERPINF1) have been found to mediate neurotrophic properties [35], anti-angiogenic properties [36], 
retinal cell survival [37] and prevent liver fibrosis through hepatic stellate cell activation [38]. The 
peptides from the S4B and S5B of maspin demonstrated here to influence VSMC behaviours in a way 
that would inhibit the build-up of atherosclerotic plaques implies a potential therapeutic use. 
This is the first report of the anti-atherogenic nature of two novel bioactive maspin peptides. In future it 
will be of benefit to determine the impact of S4B and S5B peptides on atherosclerotic plaque build-up in 
vivo. This would be further informed by generating clones expressing maspin mutated in the S4B or S5B 
regions for transfection into a suitable cell model, to directly determine the role of this region in the full 
length molecule. Other regions of maspin are also likely to be of interest, including S3C which was 
demonstrated to be associated with decreased risk of developing oesophageal squamous cell carcinoma if 
mutated by a single nucleotide polymorphism [39]. This will be pursued by studies with further 
individually matched control peptides. 
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Table Legends 
Table 1: Sequences of maspin derived peptides 
Peptides were designed from the discrete structural moieties of maspin (sequences less than 10 residues 
were excluded). The starting position of each peptide in the maspin sequence is indicated. Nomenclature 
used such that S2A is strand 2 of beta sheet A. 
Table 2: Sequences of control peptides 
Controls were matched for size and charge to the corresponding maspin peptide. 
Table 3: Sequences of attenuated peptides 
Amino acid residues were sequentially removed from each end of S5B. 
Figure Legends 
Figure 1: Adhesion of VSMC to extracellular matrix in response to maspin peptides 
Maspin peptides were screened for their ability to alter VSMC adhesion; a final concentration of 10µM 
was used for all peptides. (A) Heat map generated from xCELLigence data showing percentage increase 
or decrease (relative to C-Pep control peptide) in cell adhesion to ECM components in the presence of 
maspin peptides. CNI: collagen I, CNIV: collagen IV, FN: fibronectin, LN: laminin, VN: vitronectin. (B) 
VSMC adhesion to fibronectin (open bars) or fibrillar matrix (closed bars) in the presence of peptide S4B 
or S5B. Adhesion is expressed as percentage increase relative to specific control peptide. Statistically 
significant differences are presented as assessed by ANOVA followed by Tukey’s post-test. Panel (B) is 
combined data from three separate experiments (*p<0.05 judged using Student’s t test). Data presented as 
mean±SEM.  
Figure 2: Proliferation of VSMC on extracellular matrix in response to maspin peptides 
Maspin peptides were screened for their ability to alter VSMC proliferation; a final concentration of 
10µM was used for all peptides. (A) Heat map generated from xCELLigence data showing percentage 
increase or decrease in cell proliferation on various ECM components in the presence of maspin peptides 
after 24hours. CNI: collagen I, CNIV: collagen IV, FN: fibronectin, LN: laminin, VN: vitronectin. 
Proliferation is expressed as percentage change relative to C-Pep control peptide. Statistically significant 
differences are presented as assessed by ANOVA followed by Tukey’s post-test. (B) Proliferation in the 
presence of peptide S4B or S5B after 24 hours, compared to S4/5B control peptide as percentage relative 
to control. Panel (B) is combined data from three separate experiments (*p<0.05 judged using Student’s t 
test). Data presented as mean±SEM. 
Figure 3: Migration and invasion of VSMC after treatment with maspin peptides S4B and S5B 
The effect of peptides S4B and S5B on VSMC migration (A) and invasion through rat tail collagen gel 
(B) was determined.  Data expressed as a percentage of specific control peptide and are combined data 
from three separate experiments (p<0.05 judged using Student’s t test). Peptides were used at 10µM. Data 
presented as mean±SEM. 
Figure 4: The effect of maspin long peptide on VSMC behaviour 
VSMC adhesion, proliferation and migration in response to the maspin long peptide were investigated. 
(A) Adhesion of VSMC to ECM components in the presence of maspin long peptide. LP: long peptide, 
FN: Fibronectin, VN: vitronectin, CNI: collagen I, CNIV, collagen IV, FM: fibrillar matrix. (B) 
Proliferation of VSMC in response to long maspin peptide over 24 hours. (C) Migration of VSMC in the 
presence of long maspin peptide. All data are combined from three separate experiments (*p<0.05 judged 
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using Student’s t test) and expressed as percentage relative to long peptide control. Peptides were used at 
10µM. Data presented as mean±SEM. 
Figure 5: The effects of maspin peptides on VSMC are mediated by the engagement of ERK1/2, 
AMPK and integrins 
(A)  Expression of activated and total ERK1/2 after treatment with S4B and S5B peptides for 24 hours. 
Results shown as relative expression compared with S4/5B control peptide. (B) Expression of activated 
and total ERK1/2 after treatment with maspin long peptide. Data shown as relative expression compared 
with long peptide control. (C) Expression of activated and total AMPK after treatment with S4B and S5B 
peptides for 24 hours. Results shown as relative expression compared with S4/5B control peptide. (D) 
Expression of activated and total AMPK after treatment with maspin long peptide for 24 hours. Results 
shown as relative expression compared with maspin long peptide control. (E) Migration of VSMC in 
response to maspin long peptide after pre-treatment with AMPK inhibitor dorsomorphrin or DMSO 
carrier. Migration is expressed as percentage decrease relative to control peptide + DMSO. (F) Adhesion 
to fibronectin in response to S4B peptide after pre-treatment with function-blocking β1 integrin MAb or 
β3 integrin MAb. Adhesion is expressed as percentage increase or decrease relative to S4/5B control 
peptide. All data are combined from three separate experiments (*p<0.05 judged using Student’s t test). 
Peptides were used at 10µM. Data presented as mean±SEM. 
Figure 6: Identification of the minimal active region of S5B 
VSMC adhesion to fibronectin (A) and migration (B) in the presence of 10µM of attenuated peptides was 
determined.  Data expressed as percentage increase relative to control peptide. Data from three separate 
experiments (*p<0.05 judged using Student’s t test). Data presented as mean±SEM.  
 
Supplementary Figure 1: The effect of titrating peptides on VSMC proliferation 
VSMC proliferation was determined in the presence of titrated peptides S4B (open bars), S5B (closed 
bars) and LP (hatched bars).  Combined data from three separate experiments (*p<0.05 judged using 
Student’s t test). Data presented as mean±SEM. 
Supplementary Figure 2: S4B and S5B do not affect the proliferation of breast or prostate cancer 
cell lines 
The effect of peptides on cancer cell lines MDA-MB-231 (breast), PC3 (prostate) and DU145 (prostate) 
was determined by WST-1 assay after 48 hour incubations in 10µM of S4B (open bars), S5B (closed 
bars) or S4/5B control (hatched bars). No significant changes were observed in proliferation compared to 
the control peptide. All data are combined from three separate experiments. Data presented as 
mean±SEM. 
Supplementary Figure 3: Adhesion and proliferation of VSMC in response to maspin peptides 
Peptides were selected for further investigation based on findings from initial screening data generated 
using xCELLigence DP real time cell analyser. Individual control peptides were also designed in order to 
test the specificity of the selected peptides to alter VSMC adhesion and proliferation. (A) Percentage 
adhesion of VSMC to fibronectin compared to DMSO only control. No significant change in adhesion 
with peptides S2A, S5A or RCL compared to their respective controls. (B) Percentage adhesion of VSMC 
to fibrillar matrix compared to DMSO only control. No significant increase in adhesion with peptides 
S2A, S5A or RCL compared to their respective controls. (C) Percentage proliferation of VSMC in the 
presence of G helix and S3A peptides compared to DMSO only control. No significant change in 
proliferation compared to control peptides. All data are combined from three separate experiments. Data 
presented as mean±SEM. Peptides were used at 10µM. 
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Supplementary figure 4: Dynamic effect of peptides on the adhesion, proliferation and migration of 
VSMC 
xCELLigence plots showing VSMC adhesion to fibronectin over 4 hours (A), proliferation over 24 hours 
(B) and migration of VSMC over 24 hours (C). In all cases S4B (solid black line), S5B (dashed gray line) 
or control peptide (solid gray line). These are example plots, experiments were performed on at least 3 
separate occasions. Peptides were used at 10µM. 
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Fig. 2 
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Fig. 4 
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Fig. 5 
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Fig. 6 
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Highlights 
 
 Peptides of S4B and S5B of maspin have anti-atherogenic actions on cultured human 
VSMC 
 S4B and S5B peptides increased adhesion of VSMC to fibrillar and isolated extracellular matrix 
 S4B and S5B peptides decreased proliferation, migration and invasion of VSMC 
 A 7-mer was identified as a minimal active region 
 Peptides act through decreased ERK1/2 activation and increased levels of active AMPK 
